UPDATE 1-Regenxbio's muscle disorder therapy meets main goal in late-stage study

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00

Adds details thorughout

May 14 (Reuters) - Regenxbio RGNX.O said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study.

Shares of the company were halted in premarket trading.

The Rockville, Maryland-based company said 93% of patients with Duchenne muscular dystrophy treated with the therapy RGX-202 reached the expected level of a key protein known as microdystrophin 12 weeks after treatment.

Microdystrophin is a shortened version of dystrophin, the muscle-protecting protein missing or defective in people with the disorder.

The company said the drug was well-tolerated. It plans to seek accelerated approval in 2027.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.